Treatment regimens for managing depression in family practice

Journal of Family Practice

Volumn 52, Issue SUPPL., 2003, Pages

  Ashton, Adam Keller ^a   D'Mello, Dale A ^a   Dantz, Bezalel ^a   Hefner, Jaye ^a   Leon, F George ^a   Matson, Gary A ^a   Montano, C Brendan ^a   Pradko, James F ^a   Sussman, Norman ^a   Winsberg, Bertrand ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CYPROHEPTADINE; MIRTAZAPINE; NEFAZODONE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TRAZODONE; VENLAFAXINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDEPRESSANT AGENT; NEUROTRANSMITTER RECEPTOR;

ABDOMINAL CRAMP; AKATHISIA; ALGORITHM; AUTONOMIC DYSFUNCTION; CLINICAL TRIAL; CONFUSION; DELIRIUM; DEPRESSION; DIAPHORESIS; DIARRHEA; DISORIENTATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG RECEPTOR BINDING; DYSTONIA; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; HUMAN; HYPERTENSION; INSOMNIA; MOTOR DYSFUNCTION; MYOCLONUS; ORGASM DISORDER; PARKINSONISM; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RASH; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; STUPOR; SWEATING; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT PLANNING; TREMOR; WEIGHT GAIN; DRUG COMBINATION; DRUG EFFECT; METHODOLOGY; PHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, NEUROTRANSMITTER;

EID: 0348110650     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Croft H, Houser TL, Jamerson BD, Leadbetter R, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther 2002; 24(4):662-672.
2. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001; 9:544-551,
3. Prescribing information for Zyban, GlaxoSmithKline. 2002.
4. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34(5):649-657.
5. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158(2):282-288.
6. Perlis RH, Fava M, Nierenberg AA, et al. Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry 2002; 10(2):109-114.
7. Foote SL, Aston-Jones GS. Pharmacology and physiology of central noradrenergic systems. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, Ltd; 1995:335-345.
8. Stahl S. Essential Pharmacology. 2nd ed. New York, NY: Cambridge University Press; 2000. p.106-108.
9. Richelson E, Richelson E. Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc 1994; 69(11):1069-1081.
10. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281(6):537-44.
11. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63(4):357-66.
12. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psych 1996; 153(4):466-76.
13. Prescribing information for Effexor, Wyeth Laboratories. 2002.
14. Schatzberg AF, Cole JO, DeBattista C (eds). Manual of Clinical Pharmacology, 3rd ed. Washington, DC: American Psychiatric Press, 1997:31-112.
15. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003; 25(8):2289-2304.
16. Morishita S, Arita S. Suitable dose and duration of fluvoxamine administration to treat depression. Psychiatry Clin Neurosci 2003; 57(2):177-181.
17. Furukawa T. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev 2003; (3):CD003197.
18. Burt T, Lane RM. Forced titration as a confound in an SSRI comparator study of sertaline versus citalopram in the treatment of major depressive disorder. Biol Psychiatry 2001; 50(1):66-68.
19. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48(9):851-855.
20. Gilbody S, Witty P, Grimshaw J, Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA 2003; 289(23):3145-3151.
21. Altamura AC, Mauri M. Plasma concentrations, information and therapy adherence during long-term treatment with antidepressants. Br J Clin Pharmacol 1985; 20(6):714-716.
22. Weitzner MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002; 23(4):337-345.
23. Ashton AK, Weinstein WL. Cyproheptadine for drug-induced sweating. Am J Psychiatry 2002; 159(5):874-875.
24. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psych 1996; 153(4):466-476.
25. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl 11:37-41.
26. Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002; 51(9):753-61.
27. Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J Clin Psychiatry 2002; 63(11):981-984.
28. Settle EC Jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998; 59 Suppl 16:25-30; discussion 40-42.
29. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacotherapy 1998; 32(6):692-698.
30. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281(6):537-544.
31. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23(3):176-194.
32. Nurnberg HG, Hensley PL. Selective phosphodiesterase type-5 inhibitor treatment of serotonergic reuptake inhibitor antidepressant-associated sexual dysfunction: a review of diagnosis, treatment, and relevance. CNS Spectr 2003; 8(3):194-202.
33. Kristensen E. Sexual side effects of treatment with psychopharmaceuticals. Ugeskr Laeger 2002; 164(41):4753-4756. [in Danish]
34. Ashton AK, Rosen RC. Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Ther 1998; 24:191-192.
35. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003; 289(1):56-64.
36. Doring CM, Michoulon D, Petersen TJ, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry 2002; 14(3):143-147.
37. Wells KB Katon W, Rogers B, Camp P. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the medical outcomes study. Am J Psychiatry 1994; 151:694-700.
38. Lam RW, Wan DDC, Cohen NL, Kennedy SH. Combining antidepressants for treatment resistant depression: a review. J Clin Psychiatry 2002; 63(8):685-693.
39. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. BMJ 2001; 178:234-241.
40. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next step" practices. J Clin Psychiatry 2000; 61(6):403-408.
41. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61 Suppl 2:13-19.
42. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999; 60(1):45-49.